Endoxifen

Chemical structure of Endoxifen

Endoxifen is an active metabolite of the selective estrogen receptor modulator (SERM) tamoxifen. It is primarily responsible for the therapeutic effects of tamoxifen in the treatment of breast cancer. Endoxifen is produced in the body through the metabolism of tamoxifen by the cytochrome P450 enzyme system, particularly by the enzyme CYP2D6.

Mechanism of Action

Endoxifen functions by binding to estrogen receptors in breast tissue, thereby inhibiting the proliferative actions of estrogen on breast cancer cells. This action is crucial in the treatment of estrogen receptor-positive (ER+) breast cancer, where estrogen promotes the growth of cancer cells.

Pharmacokinetics

The pharmacokinetics of endoxifen are influenced by genetic variations in the CYP2D6 enzyme, which can affect the conversion rate of tamoxifen to endoxifen. Patients with certain genetic polymorphisms may have reduced levels of endoxifen, potentially impacting the efficacy of tamoxifen therapy.

Clinical Use

Endoxifen is not administered directly as a drug; rather, it is the active form of tamoxifen that exerts the therapeutic effects. Tamoxifen is widely used in the treatment of ER+ breast cancer in both premenopausal and postmenopausal women. The effectiveness of tamoxifen is largely attributed to the presence of endoxifen in the bloodstream.

Research and Development

Research is ongoing to develop endoxifen as a standalone therapeutic agent. This approach could potentially bypass the variability in tamoxifen metabolism and provide a more consistent therapeutic effect. Clinical trials are investigating the safety and efficacy of endoxifen in various settings, including its use in patients who are poor metabolizers of tamoxifen.

Related Pages

• Tamoxifen
• Estrogen receptor
• Breast cancer
• Cytochrome P450
• CYP2D6

This article is a stub related to pharmacology. You can help WikiMD by expanding it!